Sodium-glucose cotransporter-2 (SGLT2) inhibitors, also known as gliflozins, are a class of antidiabetic drugs initially developed to improve glycemic control in patients with type 2 diabetes mellitus (T2DM) [1,2,3]. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.